Reimbursement delays hamper cancer care

Delays in reimbursement for important cancer drugs are limiting oncologists’ ability to deliver best care for Australian patients, a medical oncologist says.  

Professor Michael Boyer, chief clinical officer at the Chris O’Brien Lifehouse in Sydney, says there are many cancer drugs available on the market that patients just can’t afford.  

“For patients that&rsquo